Get the Stockscreener App
92.00
4.74%
-4.575
Blueprint Medicines Corp stock is traded at $92.00, with a volume of 442.76K.
It is down -4.74% in the last 24 hours and down -17.49% over the past month.
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
See More
Previous Close:
$96.57
Open:
$95.28
24h Volume:
442.76K
Relative Volume:
0.55
Market Cap:
$5.89B
Revenue:
$434.41M
Net Income/Loss:
$-128.05M
P/E Ratio:
-43.60
EPS:
-2.11
Net Cash Flow:
$-250.52M
1W Performance:
-0.52%
1M Performance:
-17.49%
6M Performance:
-0.58%
1Y Performance:
-3.29%
1-Day Range:
$91.24
$95.55
1-Week Range:
$90.14
$96.72
52-Week Range:
$80.67
$121.90
Blueprint Medicines Corp Stock (BPMC) Company Profile
Name
Blueprint Medicines Corp
Sector
Industry
Phone
617-374-7580
Address
45 SIDNEY STREET, CAMBRIDGE, MA
Compare BPMC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BPMC
Blueprint Medicines Corp
|
92.07 | 5.89B | 434.41M | -128.05M | -250.52M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.16 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.71 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.58 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
113.23 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | JP Morgan | Overweight |
| Oct-24-24 | Initiated | UBS | Neutral |
| May-14-24 | Initiated | Stephens | Overweight |
| May-06-24 | Upgrade | Leerink Partners | Underperform → Market Perform |
| Oct-27-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-21-23 | Reiterated | Needham | Buy |
| Jul-31-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-05-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Jan-03-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Needham | Buy |
| Nov-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-14-22 | Initiated | Berenberg | Buy |
| Jul-08-22 | Initiated | Oppenheimer | Outperform |
| Jun-27-22 | Initiated | Wells Fargo | Underweight |
| Jun-10-22 | Downgrade | Citigroup | Neutral → Sell |
| Jun-01-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-01-22 | Initiated | Citigroup | Neutral |
| Feb-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jan-25-22 | Upgrade | Stifel | Hold → Buy |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-30-21 | Resumed | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Hold |
| Nov-02-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-02-20 | Downgrade | Jefferies | Buy → Hold |
| Oct-30-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Equal Weight |
| Mar-17-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Nov-06-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-22-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Sep-12-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-29-19 | Initiated | Piper Jaffray | Neutral |
| Aug-15-19 | Resumed | Raymond James | Mkt Perform |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-23-19 | Resumed | Goldman | Buy |
| Apr-03-19 | Initiated | Morgan Stanley | Overweight |
| Sep-25-18 | Initiated | Leerink Partners | Outperform |
| Dec-11-17 | Reiterated | Goldman | Buy |
View All
Blueprint Medicines Corp Stock (BPMC) Latest News
Blueprint Medicines stock target holds at $125 by Citizens JMP - Investing.com
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress - PR Newswire
Blueprint Medicines Corp. to Host Earnings Call - ACCESS Newswire
Blueprint Medicines’ SWOT analysis: stock outlook amid Ayvakit’s growth - Investing.com
Blueprint Medicines Co. (NASDAQ:BPMC) Stock Holdings Reduced by Rhumbline Advisers - Defense World
Blueprint Medicines COO Christina Rossi sells shares for $216,348 By Investing.com - Investing.com South Africa
Blueprint Medicines COO Christina Rossi sells shares for $216,348 - Investing.com
Blueprint Medicines Corporation (BPMC): Among the Oversold Biotech Stocks to Buy Now - Insider Monkey
Blueprint Medicines Co. (NASDAQ:BPMC) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Van ECK Associates Corp - Defense World
Blueprint Medicines (NASDAQ:BPMC) Releases Earnings Results, Misses Expectations By $0.11 EPS - MarketBeat
989 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Bought by Asset Management One Co. Ltd. - Defense World
Blueprint Medicines (NASDAQ:BPMC) Stock Rating Upgraded by StockNews.com - Defense World
Stifel maintains Blueprint Medicines stock Buy rating, $155 target By Investing.com - Investing.com South Africa
Stifel maintains Blueprint Medicines stock Buy rating, $155 target - Investing.com
Blueprint Medicines' SWOT analysis: strong ayvakit sales fuel growth as stock eyes $140 - Investing.com
What is Leerink Partnrs’ Forecast for BPMC Q1 Earnings? - Defense World
Blueprint Medicines (NASDAQ:BPMC) Lowered to Sell Rating by StockNews.com - Armenian Reporter
Stephens Inc. AR Purchases New Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
JMP Securities Reaffirms Market Outperform Rating for Blueprint Medicines (NASDAQ:BPMC) - Defense World
Blueprint Medicines’ (BPMC) Buy Rating Reiterated at Needham & Company LLC - Defense World
HC Wainwright Reaffirms “Buy” Rating for Blueprint Medicines (NASDAQ:BPMC) - Defense World
Blueprint Medicines (NASDAQ:BPMC) Rating Lowered to “Sell” at StockNews.com - Defense World
Blueprint Medicines Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Wedbush Reiterates Outperform Rating for Blueprint Medicines (NASDAQ:BPMC) - Defense World
BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline - Nasdaq
Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2024 Earnings Call Transcript - Insider Monkey
Blueprint Medicines price target raised to $135 from $127 at Baird - TipRanks
Blueprint Medicines Corporation (NASDAQ:BPMC) Is Expected To Breakeven In The Near Future - Simply Wall St
Strong Buy Rating for Blueprint Medicines: Ayvakit’s Growth Potential and Market Opportunities - TipRanks
Blueprint Medicines Corp (BPMC) Q4 2024 Earnings Call Highlights: Record Growth and Strategic ... - Yahoo Finance
Blueprint Medicines Reports Strong Growth and Promising Outlook - TipRanks
Blueprint Medicines: Positive Earnings Call Highlights Growth - TipRanks
Blueprint Medicines Corp SEC 10-K Report - TradingView
Breaking Down Blueprint Medicines: 10 Analysts Share Their Views - Benzinga
Blueprint Medicines: Q4 Earnings Snapshot - The Washington Post
Blueprint Medicines should be bought on any weakness, says Stifel - TipRanks
Earnings call transcript: Blueprint Medicines Q4 2024 misses EPS estimates - MSN
Blueprint Medicines Corp earnings missed by $0.09, revenue fell short of estimates - Investing.com
Values First Advisors Inc. Grows Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines selloff to be short-lived, says Oppenheimer - TipRanks
Earnings call transcript: Blueprint Medicines Q4 2024 misses EPS estimates By Investing.com - Investing.com UK
Blueprint Medicines Corp Reports Q4 Revenue of $144.1 Million, M - GuruFocus.com
Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings Flash (BPMC) Blueprint Medicines Posts Q4 Net Loss $-0.79 a Share, vs. FactSet Est of $-0.67 Loss - Marketscreener.com
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results - TradingView
BLUEPRINT MEDICINES Earnings Results: $BPMC Reports Quarterly Earnings - Nasdaq
Blueprint Medicines reports Q4 EPS (79c), consensus (71c) - TipRanks
Blueprint Medicines (BPMC) to Release Quarterly Earnings on Thursday - Defense World
Research Analysts Offer Predictions for BPMC FY2025 Earnings - MarketBeat
Get in on Blueprint Medicines Corp’s (BPMC) buy-in window today! - SETE News
Blueprint Medicines Corp Stock (BPMC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.93%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):